tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Nuvectis Pharma initiates NXP900 program
PremiumThe FlyNuvectis Pharma initiates NXP900 program
3M ago
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
Premium
Ratings
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
3M ago
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
Premium
Company Announcements
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
3M ago
Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
PremiumThe FlyNuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
3M ago
Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
Premium
Ratings
Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
4M ago
Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating
Premium
Ratings
Promising Developments in Nuvectis Pharma’s NXP900 Boost Buy Rating
4M ago
Promising Advancements and Financial Stability Justify Buy Rating for Nuvectis Pharma
PremiumRatingsPromising Advancements and Financial Stability Justify Buy Rating for Nuvectis Pharma
6M ago
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year
Premium
The Fly
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year
6M ago
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies
Premium
Ratings
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100